Nathan Caffo

Nessuna posizione attualmente

55 anni

Health Technology

Consumer Services

Profilo

Mr. Nathan Caffo was previously employed as a Chief Business Officer by Candel Therapeutics, Inc., a Chief Business Officer by ALX Oncology Holdings, Inc., and a President & Senior Corporate Advisor by Presage Biosciences, Inc. He received his undergraduate degree from The Pennsylvania State University.

Precedenti posizioni note di Nathan Caffo

Società	Posizione	Fine
CANDEL THERAPEUTICS, INC.	Corporate Officer/Principal	01/04/2023
ALX ONCOLOGY HOLDINGS INC.	Corporate Officer/Principal	01/09/2020
Presage Biosciences, Inc. Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA.	Amministratore Delegato	17/07/2018

Vedi nel dettaglio l'esperienza di Nathan Caffo

Formazione di Nathan Caffo

The Pennsylvania State University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Nathan Caffo

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
ALX ONCOLOGY HOLDINGS INC.	Health Technology
CANDEL THERAPEUTICS, INC.	Health Technology

Aziende private	1
Presage Biosciences, Inc. Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA.	Health Technology